Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Fitzgerald is active.

Publication


Featured researches published by Michael Fitzgerald.


American Journal of Human Genetics | 2002

A Mutation in the LDL Receptor–Related Protein 5 Gene Results in the Autosomal Dominant High–Bone-Mass Trait

Randall David Little; Colleen Folz; Susan P. Manning; Pamela Marie Swain; Shan-Chuan Zhao; Brenda Eustace; Michelle M. Lappe; Lia Spitzer; Susan Zweier; Karen Braunschweiger; Youssef Benchekroun; Xintong Hu; Ronald Adair; Linda Chee; Michael Fitzgerald; Craig Tulig; Anthony Caruso; Nia Tzellas; Alicia Bawa; Barbara Franklin; Shannon McGuire; Xavier Nogues; Gordon Gong; Kristina Allen; Anthony Anisowicz; Arturo Morales; Peter T. Lomedico; Susan M. Recker; Paul Van Eerdewegh; Robert R. Recker

Osteoporosis is a complex disease that affects >10 million people in the United States and results in 1.5 million fractures annually. In addition, the high prevalence of osteopenia (low bone mass) in the general population places a large number of people at risk for developing the disease. In an effort to identify genetic factors influencing bone density, we characterized a family that includes individuals who possess exceptionally dense bones but are otherwise phenotypically normal. This high-bone-mass trait (HBM) was originally localized by linkage analysis to chromosome 11q12-13. We refined the interval by extending the pedigree and genotyping additional markers. A systematic search for mutations that segregated with the HBM phenotype uncovered an amino acid change, in a predicted beta-propeller module of the low-density lipoprotein receptor-related protein 5 (LRP5), that results in the HBM phenotype. During analysis of >1,000 individuals, this mutation was observed only in affected individuals from the HBM kindred. By use of in situ hybridization to rat tibia, expression of LRP5 was detected in areas of bone involved in remodeling. Our findings suggest that the HBM mutation confers a unique osteogenic activity in bone remodeling, and this understanding may facilitate the development of novel therapies for the treatment of osteoporosis.


Nature | 2002

Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness

Paul Van Eerdewegh; Randall David Little; Josée Dupuis; Richard Del Mastro; Kathy Falls; Jason Simon; Dana Torrey; Sunil Pandit; Joyce McKenny; Karen Braunschweiger; Alison Walsh; Ziying Liu; Brooke Hayward; Colleen Folz; Susan P. Manning; Alicia Bawa; Lisa Saracino; Michelle Thackston; Youssef Benchekroun; Neva Capparell; Mei Wang; Ron Adair; Yun Feng; JoAnn Dubois; Michael Fitzgerald; Hui Huang; Rene Gibson; Kristina Allen; Alex Pedan; Melvyn Danzig

Asthma is a common respiratory disorder characterized by recurrent episodes of coughing, wheezing and breathlessness. Although environmental factors such as allergen exposure are risk factors in the development of asthma, both twin and family studies point to a strong genetic component. To date, linkage studies have identified more than a dozen genomic regions linked to asthma. In this study, we performed a genome-wide scan on 460 Caucasian families and identified a locus on chromosome 20p13 that was linked to asthma (log10 of the likelihood ratio (LOD), 2.94) and bronchial hyperresponsiveness (LOD, 3.93). A survey of 135 polymorphisms in 23 genes identified the ADAM33 gene as being significantly associated with asthma using case-control, transmission disequilibrium and haplotype analyses (P = 0.04–0.000003). ADAM proteins are membrane-anchored metalloproteases with diverse functions, which include the shedding of cell-surface proteins such as cytokines and cytokine receptors. The identification and characterization of ADAM33, a putative asthma susceptibility gene identified by positional cloning in an outbred population, should provide insights into the pathogenesis and natural history of this common disease.


Science | 2009

Genome Project Standards in a New Era of Sequencing

Patrick Chain; Darren Grafham; Robert S. Fulton; Michael Fitzgerald; Jessica B. Hostetler; Donna M. Muzny; J. Ali; Bruce W. Birren; David Bruce; Christian Buhay; James R. Cole; Yan Ding; Shannon Dugan; Dawn Field; George M Garrity; Richard A. Gibbs; Tina Graves; Cliff Han; Scott H. Harrison; Sarah K. Highlander; Philip Hugenholtz; H. M. Khouri; Chinnappa D. Kodira; Eugene Kolker; Nikos C. Kyrpides; D. Lang; Alla Lapidus; S. A. Malfatti; Victor Markowitz; T. Metha

More detailed sequence standards that keep up with revolutionary sequencing technologies will aid the research community in evaluating data. For over a decade, genome sequences have adhered to only two standards that are relied on for purposes of sequence analysis by interested third parties (1, 2). However, ongoing developments in revolutionary sequencing technologies have resulted in a redefinition of traditional whole-genome sequencing that requires reevaluation of such standards. With commercially available 454 pyrosequencing (followed by Illumina, SOLiD, and now Helicos), there has been an explosion of genomes sequenced under the moniker “draft”; however, these can be very poor quality genomes (due to inherent errors in the sequencing technologies, and the inability of assembly programs to fully address these errors). Further, one can only infer that such draft genomes may be of poor quality by navigating through the databases to find the number and type of reads deposited in sequence trace repositories (and not all genomes have this available), or to identify the number of contigs or genome fragments deposited to the database. The difficulty in assessing the quality of such deposited genomes has created some havoc for genome analysis pipelines and has contributed to many wasted hours. Exponential leaps in raw sequencing capability and greatly reduced prices have further skewed the time- and cost-ratios of draft data generation versus the painstaking process of improving and finishing a genome. The result is an ever-widening gap between drafted and finished genomes that only promises to continue (see the figure, page 236); hence, there is an urgent need to distinguish good from poor data sets.


Science | 2011

Comparative Functional Genomics of the Fission Yeasts

Nicholas Rhind; Zehua Chen; Moran Yassour; Dawn Anne Thompson; Brian J. Haas; Naomi Habib; Ilan Wapinski; Sushmita Roy; Michael F. Lin; David I. Heiman; Sarah K. Young; Kanji Furuya; Yabin Guo; Alison L. Pidoux; Huei Mei Chen; Barbara Robbertse; Jonathan M. Goldberg; Keita Aoki; Elizabeth H. Bayne; Aaron M. Berlin; Christopher A. Desjardins; Edward Dobbs; Livio Dukaj; Lin Fan; Michael Fitzgerald; Courtney French; Sharvari Gujja; Klavs Wörgler Hansen; Daniel Keifenheim; Joshua Z. Levin

A combined analysis of genome sequence, structure, and expression gives insights into fission yeast biology. The fission yeast clade—comprising Schizosaccharomyces pombe, S. octosporus, S. cryophilus, and S. japonicus—occupies the basal branch of Ascomycete fungi and is an important model of eukaryote biology. A comparative annotation of these genomes identified a near extinction of transposons and the associated innovation of transposon-free centromeres. Expression analysis established that meiotic genes are subject to antisense transcription during vegetative growth, which suggests a mechanism for their tight regulation. In addition, trans-acting regulators control new genes within the context of expanded functional modules for meiosis and stress response. Differences in gene content and regulation also explain why, unlike the budding yeast of Saccharomycotina, fission yeasts cannot use ethanol as a primary carbon source. These analyses elucidate the genome structure and gene regulation of fission yeast and provide tools for investigation across the Schizosaccharomyces clade.


ACS Chemical Biology | 2012

Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening

Sarah A. Stanley; Sarah Schmidt Grant; Tomohiko Kawate; Noriaki Iwase; Motohisa Shimizu; Carl N. Wivagg; Melanie R. Silvis; Edward Kazyanskaya; John Aquadro; Aaron Golas; Michael Fitzgerald; Huanqin Dai; Lixin Zhang; Deborah T. Hung

Despite the urgent need for new antitubercular drugs, few are on the horizon. To combat the problem of emerging drug resistance, structurally unique chemical entities that inhibit new targets will be required. Here we describe our investigations using whole cell screening of a diverse collection of small molecules as a methodology for identifying novel inhibitors that target new pathways for Mycobacterium tuberculosis drug discovery. We find that conducting primary screens using model mycobacterial species may limit the potential for identifying new inhibitors with efficacy against M. tuberculosis. In addition, we confirm the importance of developing in vitro assay conditions that are reflective of in vivo biology for maximizing the proportion of hits from whole cell screening that are likely to have activity in vivo. Finally, we describe the identification and characterization of two novel inhibitors that target steps in M. tuberculosis cell wall biosynthesis. The first is a novel benzimidazole that targets mycobacterial membrane protein large 3 (MmpL3), a proposed transporter for cell wall mycolic acids. The second is a nitro-triazole that inhibits decaprenylphosphoryl-β-D-ribose 2-epimerase (DprE1), an epimerase required for cell wall biosynthesis. These proteins are both among the small number of new targets that have been identified by forward chemical genetics using resistance generation coupled with genome sequencing. This suggests that methodologies currently employed for screening and target identification may lead to a bias in target discovery and that alternative methods should be explored.


Genome Research | 2010

Population genomic sequencing of Coccidioides fungi reveals recent hybridization and transposon control

Daniel E. Neafsey; Bridget M. Barker; Thomas J. Sharpton; Jason E. Stajich; Daniel J. Park; Emily Whiston; Chiung Yu Hung; Cody McMahan; Jared White; Sean Sykes; David I. Heiman; Qiandong Zeng; Amr Abouelleil; Lynne Aftuck; Daniel Bessette; Adam Brown; Michael Fitzgerald; Annie Lui; J. Pendexter Macdonald; Margaret Priest; Marc J. Orbach; John N. Galgiani; Theo N. Kirkland; Garry T. Cole; Bruce W. Birren; Matthew R. Henn; John W. Taylor; Steven D. Rounsley

We have sequenced the genomes of 18 isolates of the closely related human pathogenic fungi Coccidioides immitis and Coccidioides posadasii to more clearly elucidate population genomic structure, bringing the total number of sequenced genomes for each species to 10. Our data confirm earlier microsatellite-based findings that these species are genetically differentiated, but our population genomics approach reveals that hybridization and genetic introgression have recently occurred between the two species. The directionality of introgression is primarily from C. posadasii to C. immitis, and we find more than 800 genes exhibiting strong evidence of introgression in one or more sequenced isolates. We performed PCR-based sequencing of one region exhibiting introgression in 40 C. immitis isolates to confirm and better define the extent of gene flow between the species. We find more coding sequence than expected by chance in the introgressed regions, suggesting that natural selection may play a role in the observed genetic exchange. We find notable heterogeneity in repetitive sequence composition among the sequenced genomes and present the first detailed genome-wide profile of a repeat-induced point mutation (RIP) process distinctly different from what has been observed in Neurospora. We identify promiscuous HLA-I and HLA-II epitopes in both proteomes and discuss the possible implications of introgression and population genomic data for public health and vaccine candidate prioritization. This study highlights the importance of population genomic data for detecting subtle but potentially important phenomena such as introgression.


Nature | 2006

DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage

Michael C. Zody; Manuel Garber; David J. Adams; Ted Sharpe; Jennifer Harrow; James R. Lupski; Christine Nicholson; Steven M. Searle; Laurens Wilming; Sarah K. Young; Amr Abouelleil; Nicole R. Allen; Weimin Bi; Toby Bloom; Mark L. Borowsky; Boris Bugalter; Jonathan Butler; Jean L. Chang; Chao-Kung Chen; April Cook; Benjamin Corum; Christina A. Cuomo; Pieter J. de Jong; David DeCaprio; Ken Dewar; Michael Fitzgerald; James Gilbert; Richard Gibson; Sante Gnerre; Steven Goldstein

Chromosome 17 is unusual among the human chromosomes in many respects. It is the largest human autosome with orthology to only a single mouse chromosome, mapping entirely to the distal half of mouse chromosome 11. Chromosome 17 is rich in protein-coding genes, having the second highest gene density in the genome. It is also enriched in segmental duplications, ranking third in density among the autosomes. Here we report a finished sequence for human chromosome 17, as well as a structural comparison with the finished sequence for mouse chromosome 11, the first finished mouse chromosome. Comparison of the orthologous regions reveals striking differences. In contrast to the typical pattern seen in mammalian evolution, the human sequence has undergone extensive intrachromosomal rearrangement, whereas the mouse sequence has been remarkably stable. Moreover, although the human sequence has a high density of segmental duplication, the mouse sequence has a very low density. Notably, these segmental duplications correspond closely to the sites of structural rearrangement, demonstrating a link between duplication and rearrangement. Examination of the main classes of duplicated segments provides insight into the dynamics underlying expansion of chromosome-specific, low-copy repeats in the human genome.


PLOS Medicine | 2015

Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal

Keira A. Cohen; Thomas Abeel; Abigail Manson McGuire; Christopher A. Desjardins; Vanisha Munsamy; Terrance Shea; Bruce J. Walker; Nonkqubela Bantubani; Deepak Almeida; Lucia Alvarado; Sinéad B. Chapman; Nomonde R. Mvelase; Eamon Y. Duffy; Michael Fitzgerald; Pamla Govender; Sharvari Gujja; Susanna. Hamilton; Clinton Howarth; Jeffrey D. Larimer; Kashmeel Maharaj; Matthew Pearson; Margaret Priest; Qiandong Zeng; Nesri Padayatchi; Jacques Grosset; Sarah K. Young; Jennifer R. Wortman; Koleka Mlisana; Max O'Donnell; Bruce W. Birren

Background The continued advance of antibiotic resistance threatens the treatment and control of many infectious diseases. This is exemplified by the largest global outbreak of extensively drug-resistant (XDR) tuberculosis (TB) identified in Tugela Ferry, KwaZulu-Natal, South Africa, in 2005 that continues today. It is unclear whether the emergence of XDR-TB in KwaZulu-Natal was due to recent inadequacies in TB control in conjunction with HIV or other factors. Understanding the origins of drug resistance in this fatal outbreak of XDR will inform the control and prevention of drug-resistant TB in other settings. In this study, we used whole genome sequencing and dating analysis to determine if XDR-TB had emerged recently or had ancient antecedents. Methods and Findings We performed whole genome sequencing and drug susceptibility testing on 337 clinical isolates of Mycobacterium tuberculosis collected in KwaZulu-Natal from 2008 to 2013, in addition to three historical isolates, collected from patients in the same province and including an isolate from the 2005 Tugela Ferry XDR outbreak, a multidrug-resistant (MDR) isolate from 1994, and a pansusceptible isolate from 1995. We utilized an array of whole genome comparative techniques to assess the relatedness among strains, to establish the order of acquisition of drug resistance mutations, including the timing of acquisitions leading to XDR-TB in the LAM4 spoligotype, and to calculate the number of independent evolutionary emergences of MDR and XDR. Our sequencing and analysis revealed a 50-member clone of XDR M. tuberculosis that was highly related to the Tugela Ferry XDR outbreak strain. We estimated that mutations conferring isoniazid and streptomycin resistance in this clone were acquired 50 y prior to the Tugela Ferry outbreak (katG S315T [isoniazid]; gidB 130 bp deletion [streptomycin]; 1957 [95% highest posterior density (HPD): 1937–1971]), with the subsequent emergence of MDR and XDR occurring 20 y (rpoB L452P [rifampicin]; pncA 1 bp insertion [pyrazinamide]; 1984 [95% HPD: 1974–1992]) and 10 y (rpoB D435G [rifampicin]; rrs 1400 [kanamycin]; gyrA A90V [ofloxacin]; 1995 [95% HPD: 1988–1999]) prior to the outbreak, respectively. We observed frequent de novo evolution of MDR and XDR, with 56 and nine independent evolutionary events, respectively. Isoniazid resistance evolved before rifampicin resistance 46 times, whereas rifampicin resistance evolved prior to isoniazid only twice. We identified additional putative compensatory mutations to rifampicin in this dataset. One major limitation of this study is that the conclusions with respect to ordering and timing of acquisition of mutations may not represent universal patterns of drug resistance emergence in other areas of the globe. Conclusions In the first whole genome-based analysis of the emergence of drug resistance among clinical isolates of M. tuberculosis, we show that the ancestral precursor of the LAM4 XDR outbreak strain in Tugela Ferry gained mutations to first-line drugs at the beginning of the antibiotic era. Subsequent accumulation of stepwise resistance mutations, occurring over decades and prior to the explosion of HIV in this region, yielded MDR and XDR, permitting the emergence of compensatory mutations. Our results suggest that drug-resistant strains circulating today reflect not only vulnerabilities of current TB control efforts but also those that date back 50 y. In drug-resistant TB, isoniazid resistance was overwhelmingly the initial resistance mutation to be acquired, which would not be detected by current rapid molecular diagnostics employed in South Africa that assess only rifampicin resistance.


PLOS ONE | 2014

An improved canine genome and a comprehensive catalogue of coding genes and non-coding transcripts.

Marc P. Hoeppner; Andrew L. Lundquist; Mono Pirun; Jennifer R. S. Meadows; Neda Zamani; Jeremy Johnson; Görel Sundström; April Cook; Michael Fitzgerald; Ross Swofford; Evan Mauceli; Behrooz Torabi Moghadam; Anna Greka; Jessica Alföldi; Amr Abouelleil; Lynne Aftuck; Daniel Bessette; Aaron M. Berlin; Adam Brown; Gary Gearin; Annie Lui; J. Pendexter Macdonald; Margaret Priest; Terrance Shea; Jason Turner-Maier; Andrew Zimmer; Eric S. Lander; Federica Di Palma; Kerstin Lindblad-Toh; Manfred Grabherr

The domestic dog, Canis familiaris, is a well-established model system for mapping trait and disease loci. While the original draft sequence was of good quality, gaps were abundant particularly in promoter regions of the genome, negatively impacting the annotation and study of candidate genes. Here, we present an improved genome build, canFam3.1, which includes 85 MB of novel sequence and now covers 99.8% of the euchromatic portion of the genome. We also present multiple RNA-Sequencing data sets from 10 different canine tissues to catalog ∼175,000 expressed loci. While about 90% of the coding genes previously annotated by EnsEMBL have measurable expression in at least one sample, the number of transcript isoforms detected by our data expands the EnsEMBL annotations by a factor of four. Syntenic comparison with the human genome revealed an additional ∼3,000 loci that are characterized as protein coding in human and were also expressed in the dog, suggesting that those were previously not annotated in the EnsEMBL canine gene set. In addition to ∼20,700 high-confidence protein coding loci, we found ∼4,600 antisense transcripts overlapping exons of protein coding genes, ∼7,200 intergenic multi-exon transcripts without coding potential, likely candidates for long intergenic non-coding RNAs (lincRNAs) and ∼11,000 transcripts were reported by two different library construction methods but did not fit any of the above categories. Of the lincRNAs, about 6,000 have no annotated orthologs in human or mouse. Functional analysis of two novel transcripts with shRNA in a mouse kidney cell line altered cell morphology and motility. All in all, we provide a much-improved annotation of the canine genome and suggest regulatory functions for several of the novel non-coding transcripts.


Nature | 2006

Analysis of the DNA sequence and duplication history of human chromosome 15

Michael C. Zody; Manuel Garber; Ted Sharpe; Sarah K. Young; Lee Rowen; Keith O'Neill; Charles A. Whittaker; Michael Kamal; Jean L. Chang; Christina A. Cuomo; Ken Dewar; Michael Fitzgerald; Chinnappa D. Kodira; Anup Madan; Shizhen Qin; Xiaoping Yang; Nissa Abbasi; Amr Abouelleil; Harindra Arachchi; Lida Baradarani; Brian Birditt; Scott Bloom; Toby Bloom; Mark L. Borowsky; Jeremy Burke; Jonathan Butler; April Cook; Kurt DeArellano; David DeCaprio; Lester Dorris

Here we present a finished sequence of human chromosome 15, together with a high-quality gene catalogue. As chromosome 15 is one of seven human chromosomes with a high rate of segmental duplication, we have carried out a detailed analysis of the duplication structure of the chromosome. Segmental duplications in chromosome 15 are largely clustered in two regions, on proximal and distal 15q; the proximal region is notable because recombination among the segmental duplications can result in deletions causing Prader-Willi and Angelman syndromes. Sequence analysis shows that the proximal and distal regions of 15q share extensive ancient similarity. Using a simple approach, we have been able to reconstruct many of the events by which the current duplication structure arose. We find that most of the intrachromosomal duplications seem to share a common ancestry. Finally, we demonstrate that some remaining gaps in the genome sequence are probably due to structural polymorphisms between haplotypes; this may explain a significant fraction of the gaps remaining in the human genome.

Collaboration


Dive into the Michael Fitzgerald's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sarah Schmidt Grant

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Clinton Maddox

Southern Research Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge